Journey Medical targets expanded Emrosi coverage and EBITDA growth through 2026. The dermatology company successfully launched its internally developed oral rosacea treatment Emrosi in late March 2025, marking a significant milestone. Management expects robust prescription demand to drive revenue expansion as the company pursues broader insurance coverage for the drug. NASDAQ-listed DERM is positioning itself for profitability acceleration, with leadership focused on scaling Emrosi adoption among dermatologists and patients. The company's strategy centers on expanding reimbursement reach while managing operating expenses to achieve EBITDA growth targets. Strong prescription demand signals market confidence in the treatment's efficacy and positioning within the rosacea treatment landscape.
Post from MarketNews_en
Log in to interact with content.